| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NSPR | Common Stock | Purchase | $286K | +175K | +237.99% | $1.63 | 249K | May 12, 2023 | See footnote | F1, F2, F3 |
| holding | NSPR | Common Stock | 42.3K | May 12, 2023 | Direct |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NSPR | Series H Warrants to purchase Common Stock | Purchase | $143K | +87.5K | $1.63 | 87.5K | May 12, 2023 | Common Stock | 87.5K | $1.38 | See footnote | F2, F3, F4, F5 | |
| transaction | NSPR | Series I Warrants to purchase Common Stock | Purchase | $143K | +87.5K | $1.63 | 87.5K | May 12, 2023 | Common Stock | 87.5K | $1.38 | See footnote | F2, F3, F6, F7 | |
| transaction | NSPR | Series J Warrants to purchase Common Stock | Purchase | $143K | +87.5K | $1.63 | 87.5K | May 12, 2023 | Common Stock | 87.5K | $1.38 | See footnote | F2, F3, F8, F9 | |
| transaction | NSPR | Series K Warrants to purchase Common Stock | Purchase | $143K | +87.5K | $1.63 | 87.5K | May 12, 2023 | Common Stock | 87.5K | $1.38 | See footnote | F2, F3, F10, F11 |
| Id | Content |
|---|---|
| F1 | The shares of common stock reported in this row represent shares of restricted stock that were acquired in a private placement transaction on May 12, 2023 pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Private Placement"). |
| F2 | The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327. |
| F3 | These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes. |
| F4 | The aggregate number of warrants reported in this row consists of 87,500 Series H Warrants that were acquired in the Private Placement. |
| F5 | The Series H Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's public release of primary and secondary end points related to one year follow up study results from the Company's C-Guardians pivotal trial. |
| F6 | The aggregate number of warrants reported in this row consists of 87,500 Series I Warrants that were acquired in the Private Placement. |
| F7 | The Series I Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's announcement of receipt of Premarket Approval (PMA) from the Food and Drug Administration ("FDA") for the CGuard Prime Carotid Stent System (135 cm). |
| F8 | The aggregate number of warrants reported in this row consists of 87,500 Series J Warrants that were acquired in the Private Placement. |
| F9 | The Series J Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's announcement of receipt of FDA approval for the SwitchGuard transcarotid system and CGuard Prime 80 cm. |
| F10 | The aggregate number of warrants reported in this row consists of 87,500 Series K Warrants that were acquired in the Private Placement. |
| F11 | The Series K Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of the CGuard Carotid Stent System in the United States begin. |
Exhibit 24.1: Power of Attorney